Contracts › 75N93020C00016
75N93020C00016: To Advance a Novel Beta-Lactamase Inhibitor of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.
Awarded to Spring Mill Pharma Incorporated by National Institutes of Health (NIH).
$25.0Mobligated
$44.5Mpotential value
31 January 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93020C00016 |
|---|---|
| Awardee | Spring Mill Pharma Incorporated |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | PA |
| Offers received | 12 |
| Period of performance | 01 July 2020 to 31 January 2028 |
| Potential end | 31 January 2028 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record